syd985
mAbexperimentalADC
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Oct 1, 2014 (NCT02277717)
Timeline
Indications
Studied for
- Biomarkers · Phase 1
- Breast Neoplasms · Phase 3
- Drugs, Investigational · Phase 1
- Endometrial Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 1
- Genes, erbB-2 · Phase 1
- Intestinal Neoplasms · Phase 1
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Stomach Neoplasms · Phase 1
- Triple Negative Breast Neoplasms · Phase 1
- Urinary Bladder Neoplasms · Phase 1
Mechanism of action
ERBB2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- duocarmycin
Oral
No
Parenteral
No
Topical
No
Also known as
- syd985
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04983238 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2021 | Byondis |
| NCT04602117 | Phase 1 | Dec 1, 2020 | QuantumLeap Healthcare Collaborative |
| NCT04205630 | Phase 2 | Mar 31, 2020 | Byondis |
| NCT04235101 | Phase 1 | Mar 31, 2020 | Byondis |
| NCT03262935 | Phase 3 | Nov 30, 2017 | Byondis |
| NCT02277717 | Phase 1 | Oct 1, 2014 | Byondis |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Byondis | For profit | 5 | 5 | 3 | 2014 |
| QuantumLeap Healthcare Collaborative | Academic/Hospital | 1 | 1 | 1 | 2020 |
2 organizations
Page 1 / 1